Form 4: Tango Therapeutics President Executes Stock Option Plan

Adam Crystal, President of R&D at Tango Therapeutics, exercised options and sold 38,460 shares under a 10b5-1 plan.

Summary

• Adam Crystal, President of R&D at Tango Therapeutics, exercised stock options for 38,460 shares at a strike price of $5.20.
• Following the exercise, the reporting person sold the entire block of 38,460 shares at a market price of $25.00 per share.
• The transactions were executed on April 15, 2026, pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
• The reporting person retains beneficial ownership of 112,622 shares of common stock following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the transaction is a routine, pre-planned divestment by an executive and does not signal a change in company fundamentals.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.
• The executive maintains a significant remaining equity stake of 112,622 shares in the company.

Negatives

• The executive liquidated a portion of their holdings, which may be perceived as a reduction in direct exposure to future stock price appreciation.

Risks

• Reliance on Rule 10b5-1 plans does not eliminate the inherent market risk associated with the company's clinical development pipeline.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice in the biotechnology sector, often used by executives to manage personal liquidity while maintaining long-term alignment with company performance.

Comparison to Industry Standards

• The use of 10b5-1 plans is a best-practice standard for corporate officers to avoid potential insider trading allegations.
• The volume of shares sold is consistent with typical executive compensation and diversification strategies seen in mid-cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the sale was conducted through a pre-established, automated trading plan.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Tango Therapeutics, TNGX, Insider Trading, Form 4, Biotech, Stock Options